Company news
Xencor, Inc. news in 2021
Xencor, Inc.'s news releases, calls and decks from 2021, newest first.
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
December 11, 2021
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
November 11, 2021
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
November 11, 2021
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
November 7, 2021
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
November 3, 2021
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
November 2, 2021
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
October 31, 2021
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
October 3, 2021
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
September 30, 2021
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 19, 2021
Xencor Reports Second Quarter 2021 Financial Results
August 3, 2021
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
July 27, 2021
Xencor to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021
Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19
May 25, 2021
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
May 24, 2021
Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
May 11, 2021
Xencor Reports First Quarter 2021 Financial Results
May 4, 2021
Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021
April 27, 2021
Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases
April 27, 2021
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
April 9, 2021
Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 9, 2021
Xencor to Present at the Barclays Global Healthcare Conference
March 2, 2021
Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
February 24, 2021
Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
February 22, 2021
Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
February 15, 2021
Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer
January 5, 2021